In conclusion, this meta-analysis provides a strong evidence of the correlation of HIF-1α overexpression with both clinicopathological features and survival in patients with osteosarcomas, chondrosarcomas, and giant cell tumors of the bone, suggesting HIF-1α could be used as a useful biomarker for predicting the prognosis of bone tumor patients. Here, HIF1A is linked to bone giant cell tumor.